IL2 and COVID-19: To date, there have been very few pilot studies investigating the use of low-dose IL-2 in COVID-19 patients, and these have been limited to the treatment of patients with acute disease, which may explain the reported lack of clear therapeutic benefit for these patients [34, 35].